Switch to:
More From Other Websites
Valeant Closes Down Slightly After Completing Refi Mar 22 2017
Valeant Rearranges Deck Chairs Mar 22 2017
Relistor May Be Solid Growth Opportunity for Valeant in 2017 Mar 22 2017
Valeant's IBS-D Drug Could See Competition with FDA Changes Mar 22 2017
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma,... Mar 22 2017
Xifaxan Expected to Witness Robust Growth in 2017 Mar 22 2017
Headwinds Seen by Valeant Pharmaceuticals in 2016 Mar 22 2017
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive... Mar 21 2017
4:33 pm Valeant Pharma closed its previously announced refinancing transactions; extends maturities... Mar 21 2017
Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA Mar 21 2017
Valeant Completes Refinancing Transactions Mar 21 2017
Valeant Completes Refinancing Transactions Mar 21 2017
Valeant Completes Bond Tender Offer Mar 21 2017
Valeant’s Net Profit Margins Expected to Narrow in 2017 Mar 21 2017
Valeant's Post-Ackman Recovery Is Characterized By 'Less Money, More Problems' Mar 21 2017
Valeant Pharmaceuticals Expects Lower Revenue in 2017 Mar 21 2017
[$$] Options Traders Bet on More Big Moves in Valeant Mar 21 2017
Analysts’ Recommendations for Valeant Pharmaceuticals in 2017 Mar 21 2017
Biotech Bull Making a Comeback Mar 21 2017
With Ackman Out, Valeant Confronts Rocky Road to Revival Mar 21 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK